Results 151 to 160 of about 8,127 (167)

Effect of adenosine triphosphate on ribociclib-induced skin toxicity in rats

Cutaneous and Ocular Toxicology, 2023
© 2023 Informa UK Limited, trading as Taylor & Francis Group.Purpose: Ribociclib is a CDK4/6 inhibitor approved for the treatment of breast cancer; it inhibits the activity of CDK4/6 by competitively binding to adenosine 5'-triphosphate (ATP) binding ...
Emin Murat AkbaŞ, Halis Suleyman, Zeynep Suleyman   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Ribociclib

Reactions Weekly, 2022
  +7 more sources

Ribociclib

Reactions Weekly, 2021
  +6 more sources

Ribociclib

Reactions Weekly, 2018
openaire   +2 more sources

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

Annals of Oncology, 2021
MIGUEL Martin, Luis De La Cruz-Merino, K Petrakova   +2 more
exaly  

Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer—findings from the RIBECCA trial

European Journal of Cancer, 2022
Sara Y Brucker, Corinna Grunert, Sherko Kuemmel   +2 more
exaly  

Simple and rapid quantification of ribociclib in rat plasma by protein precipitation and LC‐MS/MS: An application to pharmacokinetics of ribociclib nanoparticles in rats

Journal of Mass Spectrometry, 2023
Osama Alshogran
exaly  

Quantification of ribociclib in dried blood spots by LC–MS/MS: Method development and clinical validation

Journal of Pharmaceutical and Biomedical Analysis, 2021
R H J Mathijssen, Monique Bos, Peter de Bruijn   +2 more
exaly  

Ribociclib Hybrid Lipid–Polymer Nanoparticle Preparation and Characterization for Cancer Treatment

Polymers, 2023
Ramadan Al-Shdefat, Osama Alshogran, Ahmed Rifaat Mohamed Gardouh   +2 more
exaly  

Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers

ESMO Open, 2020
Kristina Butler, Matthew Block, Amīnah Jatoi   +2 more
exaly